Proscia, a Philadelphia, PA-based provider of digital and computational pathology solutions, secured $23m in Series B funding.
The round, which brought its funding total to $35m, was led by Scale Venture Partners, with participation from Hitachi Ventures, the strategic corporate venture capital arm of Hitachi, Ltd.
The company will use the funds to:
- accelerate commercial expansion, ramping up its global sales, marketing, and support teams,
- further drive pathology’s data-driven future by expanding its data assets and AI application portfolio, and
- advance its regulatory strategy to secure FDA clearance.
Led by David West, CEO, Proscia is a software company advancing a digital pathology platform and a pipeline of AI-powered applications, which enable laboratories to accelerate discoveries and improve patient outcomes. The Concentriq® software platform combines enterprise scalability with AI applications to help laboratories, health systems, and life sciences companies surface new insights, accelerate breakthroughs, and improve patient outcomes.
Proscia’s customer base includes laboratory titans and digital pathology pioneers as well as 10 of the top 20 pharmaceutical companies.